Skin Cancer
Specialty Channel

Featured Article
The FDA has approved cemiplimab-rwlc, a PD-1 blocking antibody, for the treatment of patients with locally advanced basal cell carcinoma (laBCC) and has metastatic BCC (mBCC).
Study findings suggest that by including skin cancer content in cosmetology curricula, cosmetologists can be better screen their clients for suspicious lesions.
According to A. Hunter Shain, PhD, and colleagues, melanoma can be predicted long before any suspicious moles are detected thanks to the identification of DNA mutations in individual skin cells.
First-line pembrolizumab monotherapy is safe and effective for treating patients with unresectable CSCC, according to findings from a phase 2 study.
True or False: Cosibelimab has a predictable and manageable safety profile and demonstrated robust clinical activity in mCSCC patient, including durable complete and partial responses.
Preliminary safety and efficacy data presented at ESMO 2020 Virtual Congress demonstrate that cosibelimab has a manageable safety profile and meaningful clinical activity in patients with mCSCC.
Treatments for melanoma brain metastasis changed between 2007 and 2016 with the advent of new radiotherapy techniques, targeted therapeutic agents, and ______ ?
The FDA has approved atezolizumab plus cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
The evolution of RT techniques and therapies for melanoma brain metastases have improved outcomes among patients since 2007, according to a population-based study.

News

The FDA has approved cemiplimab-rwlc, a PD-1 blocking antibody, for the treatment of patients with locally advanced basal cell carcinoma (laBCC) and has metastatic BCC (mBCC).
Study findings suggest that by including skin cancer content in cosmetology curricula, cosmetologists can be better screen their clients for suspicious lesions.
According to A. Hunter Shain, PhD, and colleagues, melanoma can be predicted long before any suspicious moles are detected thanks to the identification of DNA mutations in individual skin cells.
First-line pembrolizumab monotherapy is safe and effective for treating patients with unresectable CSCC, according to findings from a phase 2 study.

Interactive Features

True or False: Cosibelimab has a predictable and manageable safety profile and demonstrated robust clinical activity in mCSCC patient, including durable complete and partial responses.
Treatments for melanoma brain metastasis changed between 2007 and 2016 with the advent of new radiotherapy techniques, targeted therapeutic agents, and ______ ?
True or False: Has pembrolizumab been approved by the FDA for use in patients with cSCC?
True or False: In a phase 2 study, combining low-dose ipilimumab with pembrolizumab led to significant antitumor activity in patients with melanoma that progressed with a PD1 antibody.
Stay in the know.
OncNet Newsletter